Indication
Dimethyl fumarate Accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
Loading your page…
Loading your page…
Multiple Sclerosis
Marketing Authorisation Holder: Accord Healthcare Ltd
EMA Authorisation: 22/04/2024
INN: dimethyl fumarate
AI Drug & Interaction Analysis
Free account required
Ask Osler about Dimethyl fumarate Accord: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.